Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 101-108

  Gershkovich, Pavel ^a   Wasan, Ellen K ^a,b   Lin, Molly ^a   Sivak, Olena ^a   Leon, Carlos G ^a   Clement, John G ^c   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA INSTITUTE OF TECHNOLOGY   (Canada)

^c ICo Therapeutics Inc   (Canada)

Author keywords

Intestinal absorption; Polyene antibiotics; Systemic fungal infections; Tissue distribution

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CREATININE; DIACYLGLYCEROL; MACROGOL 2000; MONOACYLGLYCEROL; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE ABSORPTION; KIDNEY; MICELLE; NONHUMAN; RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMAL STRUCTURES; ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; MALE; RATS; TIME FACTORS;

EID: 67249101874     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp140     Document Type: Article

References (44)

1. Gold W, Stout HA, Pagano JF et al. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiot Annu 1955; 3: 579-86.
2. Sternberg TH, Wright ET, Oura M. A new antifungal antibiotic, amphotericin B. Antibiot Annu 1955; 3: 566-73.
3. Steinberg BA, Jambor WP, Suydam LO. Amphotericins A and B: Two new antifungal antibiotics possessing high activity against deepseated and superficial mycoses. Antibiot Annu 1955; 3: 574-8.
4. Vandeputte J, Wachtel JL, Stiller ET. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. II. The isolation and properties of the crystalline amphotericins. Antibiot Annu 1955; 3: 587-91.
5. Ostrosky-Zeichner L, Marr KA, Rex JH et al. Amphotericin B: Time for a new 'gold standard'. Clin Infect Dis 2003; 37: 415-25.
6. Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43: 917-24.
7. Lemke A, Kiderlen AF, Kayser O et al. Appl Microbiol Biotechnol 2005; 68: 151-62.
8. Amidon GL, Lennernas H, Shah VP et al. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20.
9. Halde C, Newcomer VD, Wright ET et al. An evaluation of amphotericin B in vitro and in vivo in mice against Coccidioides immitis and Candida albicans, and preliminary observations concerning the administration of amphotericin B to man. J Invest Dermatol 1957; 28: 217-31; discussion, 31-2.
10. Littman ML, Horowitz PL, Swadey JG. Coccidioidomycosis and its treatment with amphotericin B. Am J Med 1958; 24: 568-92.
11. Louria DB. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiotic Med Clin Ther 1958; 5: 295-301.
12. Kravetz HM, Andriole VT, Huber MA et al. Oral administration of solubilized amphotericin B. N Engl J Med 1961; 265: 183-4.
13. Hofstra W, de Vries-Hospers HG, van der Waaij D. Concentrations of amphotericin B in faeces and blood of healthy volunteers after the oral administration of various doses. Infection 1982; 10: 223-7.
14. Robbie G, Wu TC, Chiou WL. Poor and unusually prolonged oral absorption of amphotericin B in rats. Pharm Res 1999; 16: 455-8.
15. Stoutenbeek CP, van Saene HK, Zandstra DF. The effect of oral non-absorbable antibiotics on the emergence of resistant bacteria in patients in an intensive care unit. J Antimicrob Chemother 1987; 19: 513-20.
16. Ben-Ari J, Samra Z, Nahum E et al. Oral amphotericin B for the prevention of Candida bloodstream infection in critically ill children. Pediatr Crit Care Med 2006; 7: 115-8.
17. Kayser O, Olbrich C, Yardley V et al. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003; 254: 73-5.
18. Segarra I, Movshin DA, Mannino RJ et al. Pharmacokinetics and tissue distribution of amphotericin B in mice after oral administration of AmB cochleates, a new effective lipid-based formulation for the oral treatment of systemic fungal infections. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 861, 28. American Society for Microbiology, Washington, DC, USA.
19. Delmas G, Park S, Chen ZW et al. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 2002; 46: 2704-7.
20. Amarji B, Ajazuddin, Raghuwanshi D et al. Lipid nano spheres (LNSs) for enhanced oral bioavailability of amphotericin B: Development and characterization. J Biomed Nanotechnol 2007; 3: 264-9.
21. Risovic V, Boyd M, Choo E et al. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob Agents Chemother 2003; 47: 3339-42.
22. Risovic V, Sachs-Barrable K, Boyd M et al. Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug Dev Ind Pharm 2004; 30: 767-74.
23. Risovic V, Rosland M, Sivak O et al. Assessing the antifungal activity of a new oral lipid-based amphotericin B formulation following administration to rats infected with Aspergillus fumigatus. Drug Dev Ind Pharm 2007; 33: 703-7.
24. Sachs-Barrable K, Lee SD, Wasan EK et al. Enhancing drug absorption using lipids: A case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev 2008; 60: 692-701.
25. Wasan EK, Bartlett K, Gershkovich P et al. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm 2009; doi:10.1016/j.ijpharm.2009.01.003.
26. Wasan KM, Wasan EK, Gershkovich P et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 2009, in press.
27. Chow HH, Cai Y, Mayersohn M. Disposition kinetics of amphotericin B in rats. The influence of dose. Drug Metab Dispos 1992; 20: 432-5.
28. Boswell GW, Bekersky I, Buell D et al. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob Agents Chemother 1998; 42 263-8.
29. Espada R, Josa JM, Valdespina S et al. HPLC assay for determination of amphotericin B in biological samples. Biomed Chromatogr 2008; 22: 402-7.
30. Sivak O, Bartlett K, Risovic V et al. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J Pharm Sci 2004; 93: 1382-9.
31. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: What are the differences? Clin Microbiol Infect 2008; 14 Suppl 4: 25-36.
32. Fielding RM, Singer AW, Wang LH et al. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1992; 36: 299-307.
33. Walsh TJ, Yeldandi V, McEvoy M et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998; 42: 2391-8.
34. Bekersky I, Boswell GW, Hiles R et al. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): A 91-day study in rats. Pharm Res 2000; 17: 1494-502.
35. Falk R, Grunwald J, Hoffman A et al. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis. Antimicrob Agents Chemother 2004; 48: 3606-9.
36. Vogelsinger H, Weiler S, Djanani A et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 2006; 57: 1153-60.
37. Gershkovich P, Kagan L, Hoffman A. Lymphatic absorption of nanoparticles. In: Domb AJ, Tabata Y, Ravi Kumar MNV et al., eds. Nanoparticles for Pharmaceutical Applications. Valencia, CA, USA: American Scientific Publishers, 2007.
38. Echevarria I, Barturen C, Renedo MJ et al. Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats. Antimicrob Agents Chemother 2000; 44 898-904.
39. Bekersky I, Fielding RM, Dressler DE et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46: 834-40.
40. Hong Y, Shaw PJ, Tattam BN et al. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. Eur J Clin Pharmacol 2007; 63 165-72.
41. Atkinson AJ Jr, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13: 271-6.
42. Smith PJ, Olson JA, Constable D et al. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J Antimicrob Chemother 2007; 59: 941-51.
43. Ellis M. New dosing strategies for liposomal amphotericin B in high-risk patients. Clin Microbiol Infect 2008; 14 Suppl 4: 55-64.
44. Cordonnier C, Mohty M, Faucher C et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31: 135-41.